Please assess the completion status of the following clinical trial:

Trial Title: US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent, if required~* Patient received at least 1 dose of moxetumomab pasudotox-tdfk and has completed or discontinued the treatment~* Patient has a medical record available from the start of first dose of moxetumomab pasudotox tdfk~AND at least 1 of the following:~* Patient is ≥65 years old at the time of starting initial treatment with moxetumomab pasudotox-tdfk OR~* Adult (≥18 years old) patient has moderate renal impairment, at the time of starting initial treatment with moxetumomab pasudotox-tdfk

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).